Neurocrine Biosciences Reports Strong Q1 Earnings and Announces $2.9B Soleno Therapeutics Acquisition
Summary
Neurocrine Biosciences reported robust Q1 2026 financial results, with net product sales up 43.9%, and announced a major $2.9 billion cash acquisition of Soleno Therapeutics to expand its pipeline.
Key Events
-
Strong Q1 2026 Financial Performance
Total revenues increased 42.2% year-over-year to $814.5 million, driven by a 43.9% rise in net product sales to $811.0 million. Net income surged to $197.9 million from $7.9 million in Q1 2025, with diluted EPS reaching $1.91 compared to $0.08 previously.
-
Major Acquisition of Soleno Therapeutics
The company entered into an agreement to acquire Soleno Therapeutics for approximately $2.9 billion in cash. The tender offer commenced on April 20, 2026, and the HSR Act waiting period expired on April 27, 2026, moving the transaction closer to its expected Q2 2026 close. This acquisition is a significant strategic expansion of Neurocrine's pipeline.
-
Key Product Sales Growth
INGREZZA net product sales grew to $656.9 million, while CRENESSITY, launched in December 2024, contributed $153.3 million in net product sales during the quarter, demonstrating successful commercialization.
-
Pipeline Advancement and R&D Investment
Neurocrine initiated a Phase 2 clinical study for NBI-1117570 in schizophrenia and continues to advance other programs, including osavampator in Phase 3 for MDD. R&D expenses increased to $296.2 million, reflecting continued investment in its expanded pipeline.
Analysis
Neurocrine Biosciences delivered exceptionally strong first-quarter 2026 financial results, with significant revenue and net income growth driven by its key products, INGREZZA and CRENESSITY. The company also announced a major strategic move to acquire Soleno Therapeutics for approximately $2.9 billion in cash, a transaction expected to close in Q2 2026. This acquisition, representing a substantial portion of Neurocrine's market capitalization, is a significant pipeline expansion, funded by existing cash and potentially modest debt. While the company faces ongoing legal challenges and a DOJ investigation, management does not anticipate a material adverse effect. Multiple executives also adopted new Rule 10b5-1 selling plans, a common practice for pre-planned share dispositions.
At the time of this filing, NBIX was trading at $145.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $108.35 to $160.18. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.